Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis

BACKGROUND: Multiple myeloma is a bone marrow‐based hematological malignancy accounting for approximately two per cent of cancers. First‐line treatment for transplant‐ineligible individuals consists of multiple drug combinations of bortezomib (V), lenalidomide (R), or thalidomide (T). However, acces...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cochrane Database Syst Rev
Autors principals: Piechotta, Vanessa, Jakob, Tina, Langer, Peter, Monsef, Ina, Scheid, Christof, Estcourt, Lise J, Ocheni, Sunday, Theurich, Sebastian, Kuhr, Kathrin, Scheckel, Benjamin, Adams, Anne, Skoetz, Nicole
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2019
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6876545/
https://ncbi.nlm.nih.gov/pubmed/31765002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013487
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars